Microsatellite Status, Tumor Budding, CD3 and CD8 T Cell Densities in Relation to Invasiveness, Lymph Node Involvement in Colorectal Adenocarcinoma
Keywords:
lymph node involvement, MMR, T cell densities, tumor budding, tumor differentiationAbstract
Background: Aside from the factors more commonly known as predictors in colorectal cancer, there are 3 additional less well-known factors, i.e., tumor budding (TB), T cell densities and loss of MMR protein expression, the aforementioned three factors are known to be independent predictive factors in CRC survival. In this study association of TB, T cell densities and loss of MMR protein were examined to see the association with differentiation, tumor location, invasiveness and lymph node invasiveness. Methods: A retrospective cohort study was conducted using 68 CRC Formalin Fixed Paraffin Embedded samples from patients who underwent removal surgeries with the diagnosis of adenocarcinoma not otherwise specified. TB counts were identified by immunohistochemical staining using Pan-Cytokeratin AE1/AE3 and were categorized into low and high. MMR protein loss was analyzed using antibodies MLH1 and MSH6 categorized as positive and negative, then classified into Microsatellite Stable (MSS) and Microsatellite Instability (MSI). CD3 and CD8 T cell densities were identified using CD3 Biocare Medical and CD8 Biocare, was categorized into low and high. Secondary data from medical records were collected and analyzed using SPSS 25. Results: A significant relationship was found between tumor budding with the depth of invasion and lymph node involvement (p=0.021 and 0.020). Conclusion: Tumor budding (TB) plays a role in the depth of invasion and lymph node involvement in CRC but has no significant relationship with CD3/CD8 densities, differentiation, location, and MMR status. There was also no significant relationship between MMR status with differentiation, location, depth of invasion, lymph node involvement, and TB.References
Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: Cancer today lyon. France:: International Agency for Research on Cancer; 2024 [Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf.
Fujiyoshi K, Vayrynen JP, Borowsky J, et al. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine. 2020;57:102860.
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299-311.
Lea D, Haland S, Hagland HR, Soreide K. Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era. Scand J Gastroenterol. 2014;49(10):1153-63.
Ahmed Farag AF, Elbarmelgi MY, Azim HA, Abozeid AA, Mashhour AN. TNMF versus TNM in staging of colorectal cancer. Int J Surg. 2016;27:147-50.
De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Arch. 2016;468(4):397-408.
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662-80.
De' Angelis GL, Bottarelli L, Azzoni C, et al. Microsatellite instability in colorectal cancer. Acta Biomed. 2018;89(9-S):97-101.
Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA, Jr., André T. Immune checkpoint inhibition in colorectal cancer: Microsatellite instability and beyond. Target Oncol. 2020;15(1):11-24.
Zhang Y, Zhang F, Zhao L, Fu X, Shang Y, Gao Q. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature. BMC Gastroenterol. 2021;21(1):399.
Marx AH, Mickler C, Sauter G, et al. High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. Int J Colorectal Dis. 2020;35(2):259-68.
Dhuhani I, Handjari DR, Rahadiani N, Krisnuhoni E, M S. Relationship between clinicopathological profile and tumor budding status in colorectal adenocarcinoma at Dr. Cipto Mangunkusumo General National Hospital: A retrospective study. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy. 2022;23:193-9.
Jessup JM, Goldberg RM, Asare EA, et al. Colon and rectum. In: Mahul B. Amin M, FCAP, editor. AJCC cancer staging manual. 8 ed. American College of Surgeons, 633 N Saint Clair St, Chicago, IL 60611-3211 USA: Springer; 2018. p. 251-74.
Hilbertina N, Siregar NC, Abdullah M, SI W. Determination of cancer-associated fibroblast and stromal phenotype as novel prognostic factors for colorectal carcinomas associated with tumor budding. J Nat Sc Biol Med. 2019;10:S68-72.
Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS. Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 2016;7(49):81778-90.
Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.
Remo A, Fassan M, Lanza G. Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal. Pathologica. 2016;108(3):104-9.
Jang MH, Kim S, Hwang DY, et al. BRAF-mutated colorectal cancer exhibits distinct clinicopathological features from wild-type BRAF-expressing cancer independent of the microsatellite instability status. J Korean Med Sci. 2017;32(1):38-46.
Karlberg M, Stenstedt K, Hallstrom M, Ragnhammar P, Lenander C, Edler D. Tumor budding versus mismatch repair status in colorectal cancer - An exploratory analysis. Anticancer Res. 2018;38(8):4713-21.
Andersen HS, Bertelsen CA, Henriksen R, et al. The pathological phenotype of colon cancer with microsatellite instability. Dan Med J. 2016;63(2).
Topal U, Gulcan P, Yuksel S, Teke Z, Bektas H, Duman M. The relationship between microsatellite instability in colorectal adenocarcinoma and tumor budding and histopathological parameters. Eur Rev Med Pharmacol Sci. 2023;27(20):9793-800.
Ezenkwa US, Ogun GO, Bamiro OO, et al. Pattern and Significance of Tumour Budding in Colorectal Carcinomas Using ITBCC Guidelines: a Low Resource Setting Practice Observation. J Gastrointest Cancer. 2020;51(3):1018-23.
Romiti A RM, Marchetti P, Di Cerbo A, Falcone R, Campisi G, Ferri M, Balducci G, Ramacciato G, Ruco L, Pilozzi E. Study of histopathologic parameters to define the prognosis of stage II colon cancer. International Journal of Colorectal Disease. 2019.
Archilla I, Diaz-Mercedes S, Aguirre JJ, et al. Lymph node tumor burden correlates with tumor budding and poorly differentiated clusters: A new prognostic factor in colorectal carcinoma? Clin Transl Gastroenterol. 2021;12(3):e00303.
Sogutcu N, Gumus S, Abidin Balkan AZ, Bilge H, Cakabay B. Side specific differences of tumor budding on non-metastatic colon cancer. Eur Rev Med Pharmacol Sci. 2022;26(20):7649-55.
Zlobec I, Dawson HE, Blank A, et al. Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients. Eur J Cancer. 2020;130:139-45.
Lea D, Watson M, Skaland I, et al. A template to quantify the location and density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment. Cancer Immunol Immunother. 2021;70(7):2049-57.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
